Editas Medicine : Corporate Effectiveness Report April 2025 (3731af)

Published: 2025-04-11 17:46:05 ET EDIT

Stephanie and Tristan

Corporate

Effectiveness

Addressing ESG & Long-term

Sustainability

April 2025

A MESSAGE FROM

Gilmore O'Neill

PRESIDENT & CEO

I joined Editas almost three years ago to lead the Company, as we use this extraordinary technology to create potentially life-changing in vivo gene editing medicines developed to treat diseases previously thought untreatable. During this time, we have learned a lot about the technical and business aspects of gene editing and made substantial progress in our in vivo discovery efforts. We have proved our resilience as a Company and as a community following the many challenges of the past few years. Despite the fact that all of these challenges have affected our patients, our families and friends, and our broader communities, I am proud of our employees and their dedication to our mission to develop transformative in vivo gene editing medicines for people living with serious diseases.

In 2024, Editas Medicine went through some significant changes as a company, but as a pioneer in the gene editing field, we continued to focus on driving solutions for people living with serious diseases by leveraging our world-class gene editing platform. As we reflect on this year, we are not just convinced about the potential of gene editing, especially our work in in vivo, we are seeing evidence of that potential in the proof-of- concept data and in our discovery efforts in the lab.

Editas continues to be committed to building relationships with the people who suffer from diseases which we seek to treat. We've heard from many patients about how they live their daily lives in fear of their disease while also being marginalized and mistreated because of their disease, thus diminishing their access to equitable healthcare and other health disparities. We persist in evolving and expanding our abilities to address these health disparities and continue to deepen our relationships with these patients.

Developing transformative treatments that give people living with serious diseases a better quality of life is our constant objective. Our experienced leadership team and board remain committed to delivering new, potentially life-changing medicines to patients while facilitating a safe, inclusive, and collaborative culture that is committed to our communities and respectful of our environment. Our governance structure and diverse workforce champion innovation, sustainability and long-term thinking. Our responsibilities and values are ingrained in our daily operations as we strive to fulfill our potential for all our stakeholders. We look forward to providing you with updates on our ongoing progress in achieving this goal.

Developing transformative treatments that give people living with serious diseases a better quality of life is our constant objective."

Editas Medicine is a Leader in the CRISPR-based Gene Editing Medicine Field

Leading in an Interconnected Gene Editing World

OBJECTIVES

KEY STAKEHOLDERS

Our Commitment to Patients

ENGAGE REGULARLY Seek out opportunities to learn from the communities we aim to create a treatment option for and continue to bring their voices into decision making and drug development planning.

LISTEN ACTIVELY Health and treatment is deeply personal, and there are similarities and differences across diseases, and among individuals affected by the same disease. It is critical that we listen and understand diverse perspectives.

ENGAGE AUTHENTICALLY We are optimistic about the promise of gene editing, yet there is still much to be learned. Through transparent communication about Editas Medicine and our approach to developing medicines, we hope to ensure the expectations we set are realistic.

For example, in 2022, Editas established two advisory councils- one for sickle cell disease and one for transfusion-dependentbeta thalassemia - comprised of patients and caregivers who guide and advise Editas throughout the drug development cycle.

For us, the patient and caregiver is - and must be - at the center of everything we do. We are acutely aware that gene editing represents a transformative technology that evokes both excitement and curiosity. We believe it is critical to be transparent about our science and engage responsibly with the patient and caregiver communities we seek to help.

Community Engagement

Editas is a founding member of the sickle cell C.A.R.E.S. Consortium, an initiative of the Sickle Cell Disease Association of America (SCDAA) to raise awareness about the importance of clinical trial participation and education, and therefore better options for the treatment of sickle cell disease.

As a Corporate Advisory Counsel member and sponsor of the Sick Cells ambassador program since 2022, Editas supports a volunteer network of sickle cell advocates dedicated to changing the landscape of sickle cell disease. The program aims to educate policymakers, connect the sickle cell community, and activate advocates to spread awareness to the broader community.

The Consortium is comprised of sickle cell community-based organizations (CBOs), patient and caregiver advocates, community partners and medical and research advisers. The Consortium defines problems and gaps in the SCD community, identifies strategies to address those needs and gaps, and determine the CBO, Community, and Corporate partnerships best equipped to implement those strategies to achieve significant and sustainable change.

Editas has attended Cooley's Anemia Foundation's Patient-Family

Conference since 2022 to connect with and learn from the thalassemia community. Members of the thalassemia community participated in a workshop to name our TDT clinical trial, EdiThal!

Kendall Square Association (KSA) brings the members of our purpose-driven, problem-solving ecosystem together. KSA is made up of over 150 organizations across Kendall Square. From major employers to local nonprofit organizations, independent restaurants and retailers, and startups, KSA represents the entire Kendall ecosystem. KSA is committed to connecting people and building community, elevating and amplifying the game-changing work that happens here, and advocating for the needs of its members.

Life Science Cares (LSC) has leveraged the talent, passion, and community investments of the life science industry to fight poverty and provide a platform for the city's leading industry to make a difference in the community. Through partnerships with life science companies and executives, LSC has invested more than $20 million and tens of thousands of volunteer hours in community-based organizations and programs that provide access to basic needs, education, and economic opportunity. Editas has been a corporate partner of LSC since 2016.

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. As the global voice of the sector, ARM represents more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.

Editas is honored to support and learn from community partners to raise awareness and understanding of the serious diseases we aim to create treatments for. Together, we work to meet unmet needs and improve the lives of patients.

Executive Compensation Philosophy

Our goal is to implement an executive compensation program that attracts and retains qualified and talented executives, motivates such executives to achieve our business goals and rewards them for short-and long-term performance with a simple and clear compensation structure.

Maintain and evaluate annually an industry-specific peer group for benchmarking pay

(through annual cash bonuses and equity awards)

• Maintain a compensation recovery or "clawback" policy

• Set robust executive and non-employee director

Stock Ownership Guidelines

• Use multiple performance measures to

determine incentive payouts, include caps on annual

incentive payments

DON'T

• Engage an independent compensation consultant

Performance Based Executive Compensation Model

Incentives linked to actions that create sustainable stockholder value

Significant equity focus strengthens alignment of interests with those of long-term stockholders

Significant majority of pay is at-risk

No guaranteed bonus or awards

No guaranteed employment term

2024 Target

Executive Compensation1

FY24 CEO Target Pay

FY24 Average NEO

Mix

Target Pay Mix

13%

24%

66%

10%

79%

76%

87%

Base

Target

Equity Grant Date

Variable

Salary

Bonus

Fair Value

Pay

1 Charts reflect target 2024 pay mix (excluding benefits) for Gilmore O'Neill, our Chief Executive Officer, and for our other named executive officers. Please see our proxy statement for the 2025

annual meeting of stockholders, available from the Securities and Exchange Commission, for additional information.

Experienced Board of Directors

Jessica Hopfield, Ph.D.

Bernadette Connaughton

Chair since 2024; Independent director since 2018

Independent director since 2021

Principal,

Former President, Intercontinental,

J. Hopfield Consulting

Bristol Myers Squibb

Gilmore O'Neill, M.B., M.M.Sc.

David Scadden, M.D.

President and CEO,

Independent director since 2019

Editas Medicine

Gerald & Darlene Jordan Professor of

Medicine

Harvard University

Andrew Hirsch

Independent director since 2017

President & CEO,

C4 Therapeutics

Elliott Levy, M.D.

Independent director since April 2023

Venture Partner,

5AM Venture Management, LLC

Board Composition

EDITAS COMMITTEES

NAME & AGE

OTHER PUBLIC DIRECTORSHIPS

NCG

OLC

Bernadette Connaughton, 66

Halozyme Therapeutics (HALO)

Zealand Pharma (ZEAL)

Andrew Hirsch, 54

C4 Therapeutics (CCCC)

Jessica Hopfield, 60

Insulet Corporation (PODD)

Chair

Maravai LifeSciences Holdings (MRVI)

Elliot Levy, 66

Omega Therapeutics, Inc. (OMGA)

NuCana plc (NCNA)

David Scadden, 72

Agios Pharmaceuticals (AGIO)

Carisma Therapeutics

Gilmore O'Neill, 60

Unity Biotechnology, Inc. (UBX)

A=Audit Committee

NCG=Nominating and Corporate Governance Committee

MEMBER

CHAIR

OLC=Organization, Leadership and Compensation Committee

YEARS

AVERAGE AGE OF

BOARD MEMBER

Index Average = 62.3 years

YEARS

AVERAGE TENURE

ON EDITAS' BOARD

Index Average = 9.4 years

33%

WOMEN

Index Average = 29.2 %

Index averages based on Russell 3000 constituents; The Conference Board (2024)

Disclaimer

Editas Medicine Inc. published this content on April 10, 2025, and is solely responsible for the information contained herein. Distributed via , unedited and unaltered, on April 11, 2025 at 21:45 UTC.